Cardiogen
A synthetic tetrapeptide (Ala-Glu-Asp-Arg) from the Khavinson bioregulator family, studied for cardiovascular tissue bioregulation and cardiac geroprotection.
Also referenced as: AEDR, Ala-Glu-Asp-Arg
Also appears in: Longevity
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Cardiovascular. Also surfaces under Longevity for browsing and discovery.
AEDR, Ala-Glu-Asp-Arg
FDA label signal · 4 trials · 43 PubMed results
Current evidence for Cardiogen is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Cardiogen has 1 name-matched clinical trial (highest phase: no phased trial) and 43 PubMed-indexed publications and is not FDA-approved. Note: 1 retracted publication in the literature.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Cardiogen?
Cardiogen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Arg (AEDR), developed as part of the Khavinson bioregulator peptide program. It is classified as a cardiovascular-tissue bioregulator, theorized to support cardiac and vascular function through tissue-specific gene modulation.
How it works
- Cardiac gene regulation — short peptides are proposed to modulate gene expression in cardiac tissue, supporting myocardial function in aging (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
- Vascular support — the peptide is theorized to interact with endothelial cell DNA to maintain vascular integrity, though specific gene targets remain uncharacterized in Western literature
Research status
- Khavinson (2005) reviewed cardiovascular applications of peptide bioregulators (Gerontology, 51(2):70–75)
- Anisimov et al. (2003) reported broader geroprotective effects of bioregulator peptide preparations (Annals of the New York Academy of Sciences, 992:141–147)
- No specific Western peer-reviewed clinical trials for Cardiogen have been published
Key considerations
- Part of the Khavinson bioregulator family — same research group and proposed mechanism as other organ-specific peptides
- Limited independent replication outside the originating research group
- Available from research vendors as lyophilized powder or capsules (typically 10–20mg)
- Often sold in combination packs with other Khavinson bioregulators